Roquefort Therapeutics plc

Roquefort Therapeutics plc is a pioneering biotechnology company dedicated to developing innovative oncology medicines. Listed on the LSE Main Market, Roquefort Therapeutics focuses on creating first-in-class drugs within the high-growth oncology segment, with a strategic vision to partner with or sell to major pharmaceutical companies after the pre-clinical phase.

Based in London, GB, Roquefort Therapeutics has built a robust portfolio of fully funded, novel, and patent-protected pre-clinical anti-cancer medicines. The company's strategic acquisitions, including Lyramid Pty Limited and Oncogeni Ltd, have expanded its capabilities in targeting Midkine and developing innovative cell and RNA oncology medicines. Roquefort Therapeutics’ diverse portfolio includes Midkine antibodies, Midkine RNA therapeutics, MK cell therapy, and siRNA targeting novel STAT-6, each demonstrating significant in vivo efficacy.

Roquefort Therapeutics plc is committed to advancing cancer treatment through cutting-edge research and development. To further explore opportunities for collaboration and product integration, we invite the management of Roquefort Therapeutics plc to create a customized and exclusive company showcase and product listing on our platform.